Buprenorphine, the active ingredient in Suboxone, is an opioid partial agonist used to treat opioid addiction. Standard drug screenings do not typically detect this substance. Specialized assays are required to identify buprenorphine or its metabolite, norbuprenorphine, in urine, blood, or saliva samples.
The need for specific testing for buprenorphine stems from its increasing prevalence as a medication-assisted treatment for opioid use disorder. Its effective use in managing withdrawal symptoms and cravings has led to its widespread adoption. Consequently, certain monitoring programs, pain management clinics, and employers require detection of this medication to ensure compliance and prevent misuse.